Sonoma Pharmaceuticals, Inc. short interest in 2022
In 2022, Sonoma Pharmaceuticals, Inc.'s disclosed short interest ran from 3.45% of shares outstanding on 14 Jan 2022 to 1.65% on 30 Dec 2022, a change of -1.80 percentage points. The year's high was 5.99% on 13 May 2022 and its low 0.19% on 15 Sep 2022, averaging 2.06% across 19 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 5.56 days on 15 Dec 2022. Full history: Sonoma Pharmaceuticals, Inc..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 3.45% (14 Jan 2022)
- End of year
- 1.65% (30 Dec 2022)
- Change
- -1.80 pp
- High
- 5.99% (13 May 2022)
- Low
- 0.19% (15 Sep 2022)
- Average
- 2.06%
- Highest days to cover
- 5.56 (15 Dec 2022)
- SEC filings marked
- 4
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 3.45% | 4.08 | |
| 31 Jan 2022 | 2.69% | 1.01 | |
| 15 Feb 2022 | 1.77% | 2.27 | 10-Q filed |
| 28 Feb 2022 | 1.21% | 1.40 | |
| 15 Mar 2022 | 1.65% | 1.70 | |
| 31 Mar 2022 | 1.59% | 1.00 | |
| 14 Apr 2022 | 2.94% | 1.44 | |
| 29 Apr 2022 | 2.51% | 2.88 | |
| 13 May 2022 | 5.99% | 1.00 | |
| 15 Jul 2022 | 0.68% | 1.35 | 10-K filed |
| 29 Jul 2022 | 0.93% | 1.00 | |
| 15 Aug 2022 | 0.44% | 1.00 | 10-Q filed |
| 31 Aug 2022 | 0.24% | 1.00 | |
| 15 Sep 2022 | 0.19% | 1.00 | |
| 31 Oct 2022 | 0.24% | 1.00 | |
| 15 Nov 2022 | 4.88% | 1.00 | 10-Q filed |
| 30 Nov 2022 | 3.09% | 4.75 | |
| 15 Dec 2022 | 3.06% | 5.56 | |
| 30 Dec 2022 | 1.65% | 1.14 |
See also: Sonoma Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.